Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2005
09/22/2005WO2005056547A3 Quinoxalines useful as inhibitors of protein kinases
09/22/2005WO2005056524A3 Therapeutic agents useful for treating pain
09/22/2005WO2005054809A3 Irciniastatins a and b
09/22/2005WO2005053719A3 Compositions for the treatment of diseases of the oral cavity and upper respiratory tract
09/22/2005WO2005049034A3 Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
09/22/2005WO2005046675A3 Methods for enhancing glutathione peroxidase activity
09/22/2005WO2005046594A3 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders
09/22/2005WO2005046567A3 Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
09/22/2005WO2005044093A3 Delta-9- the treatment of multiple sclerosis
09/22/2005WO2005041984B1 Compositions and treatments for envelope virus infections
09/22/2005WO2005041869A3 Process for co-spray drying agents with dry silicified mcc
09/22/2005WO2005039639B1 Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker
09/22/2005WO2005037208A3 Nitrone compounds prodrugs and pharmaceutical compositions of the same to treat human disorders
09/22/2005WO2005032527B1 Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy
09/22/2005WO2005030258A3 Small molecule compositions and methods for increasing drug efficiency using compositions thereof
09/22/2005WO2005023759A3 Heterocyclic inhibitors of mek and methods of use thereof
09/22/2005WO2005023184A3 Antibiotic product, use and formulation thereof
09/22/2005WO2005020957A3 Stepwise delivery of topiramate over prolonged period of time
09/22/2005WO2005020915A3 Silver dihydrogen citrate compositions comprising a second antimicrobial agent
09/22/2005WO2005016876A3 Cyclic amine bace-1 inhibitors having a benzamide substituent
09/22/2005WO2005007169A3 Liposomes containing phosphate glycerol groups for treating acute inflammatory condition
09/22/2005WO2005007131A3 Propofol formulations with non-reactive container closures
09/22/2005WO2005007069A3 Soft gel formulations for saquinavir
09/22/2005WO2005004802A3 N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease
09/22/2005WO2005002576A8 Imidazole derivatives and their use as protein kinases inhibitors
09/22/2005WO2004105686A3 Novel topical steroid cream formulations
09/22/2005WO2004098505A3 Attenuation of ischemia/reperfusion injury
09/22/2005WO2004089308A3 Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
09/22/2005WO2004064833A8 Clindamycin phosphate foam
09/22/2005WO2003099270A8 Methods of treating allergic reactions
09/22/2005WO2000075279A3 Nucleotide sequences for gene regulation and methods of use thereof
09/22/2005US20050209551 Detoxification and breast health preparations
09/22/2005US20050209463 Novel compound having antitumor activity and process for producing the same
09/22/2005US20050209462 Synthesis of benzimidate from benzoic acid
09/22/2005US20050209459 Processes for the preparation of 1,5-diryl-3-substituted-pyrazoles
09/22/2005US20050209456 Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents
09/22/2005US20050209454 Synthetic process
09/22/2005US20050209452 Proliferative disorders; cancer; 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
09/22/2005US20050209451 Crystalline form of cefdinir
09/22/2005US20050209345 Lymphatic drug delivery system
09/22/2005US20050209343 Percutaneous absorption promoters and compositions for treating athlete's foot
09/22/2005US20050209342 preparation of crystalline sertraline hydrochloride Form II substantilly free of other polymorphic forms of sertraline hydrochloride, preferably on an industrial scale. seeding and adding hydrochloric acid to form salt
09/22/2005US20050209341 R-(-)-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane or its hydrochloride salt; inhibiting the uptake of norepinephrine and serotonin; antidepressants, analgesics; treating sleep disorders, autism, psychological disorders, eating disorders
09/22/2005US20050209340 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
09/22/2005US20050209339 treating chronic rhinosinusitis such as allergic fungal sinusitis comprising daily oral administration of a composition from more than 500 mg to about 800 mg, preferably about 625 mg or 725 mg terbinafine base equivalent as hydrochloride
09/22/2005US20050209338 Phenethanolamine derivatives for treatment of respiratory diseases
09/22/2005US20050209337 Process for the preparation of prostaglandin derivatives
09/22/2005US20050209336 EP2 receptor agonists
09/22/2005US20050209335 treatment of graft versus host disease and other autoimmune diseases, organ transplant rejection, acute myeloid leukemia and T-cell non-Hodgkin's lymphoma other than cutaneous T-cell lymphoma in patients by administration of TARGRETIN
09/22/2005US20050209334 Treatment of cancer using benzoic acid derivatives
09/22/2005US20050209333 Malonamic acids and derivatives thereof as thyroid receptor ligands
09/22/2005US20050209332 cis (Z) and trans (E) stereoisomers of 4-t-butylgabapentin; synthesis starting from 4-tert-butylcyclohexanone and ethyl cyanoacetate; chemical intermediate comprising 1-carboxymethyl-1-carbamoylmethyl-4-tert-butyl-cyclohexane; neurodegenerative disorders
09/22/2005US20050209331 An amount of at least one photolabile compound or a compound converted into a photolabile compound when present in the skin is applied to the region of skin. The photolabile compound generates a biologically active agent when in the skin and the skin exposed to sunlight. is allowed to penetrate
09/22/2005US20050209330 Applying 5-aminolevulinic acid to region of the skin and exposing the region to sunlight; stimulates skin metabolism and rejuvenation and kills bacteria on the skin surface, preventing the appearance of acne
09/22/2005US20050209329 Potentiation of therapeutic effects of fatty acids
09/22/2005US20050209328 Alphahydroxyacid and one or more metals wherein the total metal concentration is less than 1000 mu g/kg and the concentration of any individual metal of the composition is less than 250 mu g/kg; use as post-etch cleaners in processing electronic devices such as semiconductors
09/22/2005US20050209327 Novel process for manufacture of quaternary ammonium tosylate salts of cinnamidoalkylamines and / or benzamidoalkylamines
09/22/2005US20050209326 Therapeutic uses for nitric oxide inhibitors
09/22/2005US20050209325 Novel interleukin-1 and tumor necrosis factor-alpha modulators, syntheses of said modulators and methods of using said modulators
09/22/2005US20050209324 Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
09/22/2005US20050209322 Sodium ferric gluconate complexes and method of manufacture thereof
09/22/2005US20050209321 Such as cyclohexane-trans-1,2-diaminetetraacetic-acid-monoplatinum
09/22/2005US20050209320 Compounds comprise an androgen receptor (AR) binding moiety which selectively targets the compounds to AR-expressing cancer cells, and a cytotoxic alkylating moiety, such as a nitrogen mustard moiety; (2R)-2-hydroxy-3-[(4-hydroxyphenyl)thio]-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
09/22/2005US20050209319 Treatment of local pain
09/22/2005US20050209317 Method and compositions for treatment of chronic neuropathic pain
09/22/2005US20050209316 Lactone formulations and method of use
09/22/2005US20050209315 Bioavailable nutritional supplement and method of treatment of malabsorption
09/22/2005US20050209314 Novel benzopyran analogs and their use for the treatment of glaucoma
09/22/2005US20050209312 Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
09/22/2005US20050209311 C7 lactyloxy-substituted taxanes
09/22/2005US20050209310 Methods for modulating tumor growth and metastasis
09/22/2005US20050209309 Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same
09/22/2005US20050209308 Coniosulfides and their derivatives, processes for preparing them, and their use as pharmaceuticals
09/22/2005US20050209307 Cardiovascular disorders; antiarrhythmia agents as result od analgesics, anesthetics
09/22/2005US20050209306 Crystalline [R-(R*,R*)]-2-(4-fluorophenyI)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl- 4-[(phenylamino)carbonyl]-1H-pyrrole-heptanoic acid calcium salt (2:1)
09/22/2005US20050209305 Methods for the production of biliverdin
09/22/2005US20050209303 Method of treatment for high neurotransmitter pattern
09/22/2005US20050209302 Glycogen synthase kinase (GSK-3) inhibitors; diabetes, neurodegenerative diseases, stroke, neurotraumatic injuries and bipolar disorders; 5-acetyl-3-[3-(methoxycarbonylpropylamino)-(benzo-[1.3]dioxyo-5-yl)-methylidene]-2-indolinone for example
09/22/2005US20050209301 Resistance-repellent retroviral protease inhibitors
09/22/2005US20050209300 Methods of treating a disorder
09/22/2005US20050209299 Inhibition of mixed lineage kinases and uses therefor
09/22/2005US20050209298 treating rheumatoid arthritis by photodynamic therapy (PDT), by administering an iminochlorin aspartic acid porphyrin derivative called ATX-S10 sodium salt; determining the location of a sentinel lymph node and the presence of cancer metastasis; compounds from US patent 6063777
09/22/2005US20050209297 Pyrazole derivatives
09/22/2005US20050209295 Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
09/22/2005US20050209294 Reacting alkali metal salt of 1,2,4-triazole with alpha-halo substituted tolunitrile in presence of dimethylformamide; intermediate in manufacture of 4,4'-[1H-1,2,4-triazol-1-ylmethylene]bisbenzonitrile (Letrozole); by-product inhibition, efficiency; treatment of hormone-dependent breast cancer
09/22/2005US20050209293 Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
09/22/2005US20050209292 Cancer therapy
09/22/2005US20050209289 Method for vascular dysregulation
09/22/2005US20050209288 Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
09/22/2005US20050209287 3-thio-4,5-disubstituted-4H-1,2,4-triazoles; Inhibiting RNase H activity, and RNA dependent DNA polymerase (RDDP) activity of HIV reverse transcriptase; 4-benzyl-3-(benzylthio)-5-(2-furyl)-4H-1,2,4-triazole for example; retrovirus-associated cancer; drug screeening
09/22/2005US20050209286 RXR activating molecules
09/22/2005US20050209285 Diseases with abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, alpha and beta SAPK2 kinases; antiproliferative; pyrrolo[2,3-d]pyrimidine-7-carboxylic acid [3-phenylcarbamoyl-phenyl]-amides and pyrrolo[3,2-c]pyridine analogs
09/22/2005US20050209284 Tec kinase inhibitors
09/22/2005US20050209282 Inhibitors of voltage-gated sodium channels; acute, chronic, neuropathic, or inflammatory pain such as femur cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; neuropathic low back pain; myofascial pain syndrome; fibromyalgia
09/22/2005US20050209280 Diagnostic agent, method for detecting a carcinoma, and means for the treatment thereof
09/22/2005US20050209279 Process for production of piperidine derivatives
09/22/2005US20050209278 Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
09/22/2005US20050209277 Such as N'-(1H-benzimidazol-2-ylmethyl)-N'-5,6,7,8-tetrahydroquinolin-8-yl-1,4-butanediamine; making chemokine receptor (CXCR4) antagonists useful as HIV antivirals; reacting a 5,6,7,8-tetrahydroquinolinylamine with an alkyl aldehyde bearing a phthalimide or a di-tert-butoxycarbonyl protecting group
09/22/2005US20050209276 Etherification, dehalogenation; filtration, crystallization; bactericides
09/22/2005US20050209275 Beta 2-adrenergic receptor agonists
1 ... 4531 4532 4533 4534 4535 4536 4537 4538 4539 4540 4541 4542 4543 4544 4545 4546 4547 4548 4549 4550 4551 ... 7860